These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11173054)

  • 1. Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model.
    Barbolosi D; Iliadis A
    Comput Biol Med; 2001 May; 31(3):157-72. PubMed ID: 11173054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.
    Iliadis A; Barbolosi D
    Comput Biomed Res; 2000 Jun; 33(3):211-26. PubMed ID: 10860586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dosage regimen optimization in cancer chemotherapy using a mathematical model].
    Barbolosi D; Freyer G; Ciccolini J; Iliadis A
    Bull Cancer; 2003 Feb; 90(2):167-75. PubMed ID: 12660135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
    Clairambault J
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal drug regimens in cancer chemotherapy: a multi-objective approach.
    Batmani Y; Khaloozadeh H
    Comput Biol Med; 2013 Dec; 43(12):2089-95. PubMed ID: 24290925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.
    El-Kareh AW; Secomb TW
    Neoplasia; 2000; 2(4):325-38. PubMed ID: 11005567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles.
    Rodallec A; Fanciullino R; Lacarelle B; Ciccolini J
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):599-610. PubMed ID: 29768060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
    Li J; Jameson MB; Baguley BC; Pili R; Baker SD
    Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal control for a cancer chemotherapy problem with general growth and loss functions.
    Murray JM
    Math Biosci; 1990 Mar; 98(2):273-87. PubMed ID: 2134507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some optimal control problems in cancer chemotherapy with a toxicity limit.
    Murray JM
    Math Biosci; 1990 Jun; 100(1):49-67. PubMed ID: 2134468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?
    Ledzewicz U; Schättler H
    Cancer Lett; 2017 Aug; 401():74-80. PubMed ID: 28323033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Array of translational systems pharmacodynamic models of anti-cancer drugs.
    Ait-Oudhia S; Mager DE
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):549-565. PubMed ID: 27771815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach.
    Ledzewicz U; Wang S; Schattler H; Andre N; Heng MA; Pasquier E
    Math Biosci Eng; 2017 Feb; 14(1):217-235. PubMed ID: 27879129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of an in vitro chemotherapy to avoid resistant tumours.
    Carrère C
    J Theor Biol; 2017 Jan; 413():24-33. PubMed ID: 27864095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
    Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
    Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy.
    Cho H; Levy D
    Bull Math Biol; 2017 Dec; 79(12):2986-3012. PubMed ID: 29022203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
    Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
    J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.